Xcyte Therapies, Inc. Announces Quarterly Dividend for 6% Convertible Exchangeable Preferred Stock.SEATTLE -- First graph, last sentence should read: The dividend on the Preferred Stock Stock shares that have preferential rights to dividends or to amounts distributable on liquidation, or to both, ahead of common shareholders. Preferred stock is given preference over common stock. Holders of preferred stock receive dividends at a fixed annual rate. will be paid on May 2, 2005...(sted May 12, 2005). The corrected release reads: XCYTE THERAPIES, INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . ANNOUNCES QUARTERLY DIVIDEND FOR 6% CONVERTIBLE EXCHANGEABLE PREFERRED STOCK Convertible exchangeable preferred stock Convertible preferred stock that may be exchanged, at the issuer's option, into convertible bonds that have the same conversion features as the convertible preferred stock. Xcyte Therapies, Inc. ("Xcyte", the "Company") (Nasdaq:XCYT) announced today that the Company's Board of Directors has declared a quarterly dividend in the amount of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock (the "Preferred Stock") in accordance with the terms thereof. Xcyte issued 2,990,000 shares of the Preferred Stock in November 2004. As of April 8, 2005, approximately 943,000 shares of the Preferred Stock have been converted to the Company's common stock. The dividend on the Preferred Stock will be paid on May 2, 2005, to the holders of record as of the close of business on April 22, 2005. Xcyte Therapies, Inc. is a biotechnology company developing a new class of therapeutic products designed to enhance the body's natural immune responses to treat cancer, infectious diseases and other medical conditions associated with weakened immune systems. Xcyte derives its therapeutic products from a patient's own T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. , which are cells of the immune system that orchestrate immune responses and can detect and eliminate cancer cells and infected cells in the body. Xcyte uses its patented and proprietary Xcellerate(TM) Technology to generate activated T cells, called Xcellerated T Cells(TM), from blood that is collected from the patient. Activated T cells are T cells that have been stimulated to carry out immune functions. The Xcellerate(TM) Technology is designed to rapidly activate and expand the number of the patient's T cells outside of the body. Xcyte is currently conducting clinical trials of Xcellerated T Cells(TM) in patients with chronic lymphocytic leukemia chronic lymphocytic leukemia n. Abbr. CLL Lymphocytic leukemia occurring mainly in older adults, characterized by slow onset and gradual progression of symptoms. , non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma , and multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . Xcyte(TM), Xcyte Therapies(TM), Xcellerate(TM) and Xcellerated T Cells(TM) are trademarks of Xcyte Therapies, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion